FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

December 17, 2019 – The FDA has approved a supplemental new drug application for enzalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. The approval is based on findings from the phase III ARCHES trial, in which the median radiographic progression-free survival (rPFS) in men with metastatic castration-sensitive prostate cancer was not reached with enzalutamide plus androgen deprivation therapy (ADT) and was 19.45 … (leggi tutto)